An international research team, spearheaded by the University of Edinburgh and King’s College London, examined data from over five million individuals across 29 nations. This extensive demographic range enabled the identification of 70 genetic variations associated with depression, half of which were previously unstudied. The research, published in the journal Cell, encompassed participants from a variety of ethnic backgrounds, facilitating the discovery of genetic variations not previously linked to depression and enhancing understanding of their role in the condition’s development.
Depression affects approximately 280 million people globally, and while life’s hardships and stress contribute to the condition, there is also a genetic component. The studied DNA changes are linked to neurons in various brain regions, including those governing emotions. Researchers anticipate that these findings will enable more precise depression risk predictions, irrespective of a patient’s ethnicity, and the creation of more diverse treatment options.
Over 1,600 drugs were examined for their impact on depression-associated genes. Besides known antidepressants, new potential medications were identified. For instance, Pregabalin and Modafinil, initially used for chronic pain and narcolepsy, respectively, demonstrated an effect on the same genes as antidepressants. Further clinical trials are required to definitively assess their efficacy in treating depression. The researchers hope that these findings will help diminish healthcare access disparities and enhance the quality of life for millions globally.
